(Q43793814)

26 November 2017

title

Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency (English)

1 reference

26 November 2017

Timothy J Franxman

1

1 reference

26 November 2017

Laura E Howe

series ordinal

2

1 reference

26 November 2017

James R Baker

series ordinal

3

1 reference

26 November 2017

language of work or name

1 reference

27 July 2014

1 reference

Journal of Clinical Immunology

26 November 2017

published in

1 reference

26 November 2017

volume

34

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

820-827

1 reference

https://scigraph.springernature.com/pub.10.1007/s10875-014-0079-3

26 November 2017

exact match

0 references

cites work

Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

How I treat common variable immune deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Granulomatous disease in common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Etanercept treatment of cutaneous granulomas in common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Morbidity and mortality in common variable immune deficiency over 4 decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

TACI is mutant in common variable immunodeficiency and IgA deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0079-3

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment

21 January 2018

1 reference

12 December 2020

Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group

1 reference

12 December 2020

Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences

1 reference

12 December 2020

TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease

1 reference

12 December 2020

Tumor necrosis factor plays a role in Schistosoma mansoni egg-induced granulomatous inflammation

1 reference

12 December 2020

Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes

1 reference

12 December 2020

Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein

1 reference

12 December 2020

Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis.

1 reference

12 December 2020

Granulomatous disease in common variable immunodeficiency

1 reference

12 December 2020

Caseating granulomatous disease in common variable immunodeficiency treated with infliximab

1 reference

12 December 2020

Noncaseating granulomatous disease in common variable immunodeficiency

1 reference

12 December 2020

Granulomatous disease in common variable immunodeficiency

1 reference

12 December 2020

Common variable immunodeficiency and granulomatosis treated with infliximab

1 reference

12 December 2020

Soluble receptors in human disease

1 reference

12 December 2020

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

1 reference

12 December 2020

Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency

1 reference

12 December 2020

10.1007/S10875-014-0079-3

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

1000389296

0 references

1 reference